Regeneron and Adverum are key players in the R&D for solutions targeting wet age-related macular degeneration (AMD), a market driven by aging populations and advanced AI diagnostics.
1 report, 1 independent
Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Regeneron and Adverum are key players in the R&D for solutions targeting wet age-related macular degeneration (AMD), a market driven by aging populations and advanced AI diagnostics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
Coverage
Newest first; wire copies grouped- GlobeNewswireWet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape The global wet